Drug class profile · refreshed daily from federal data

Phosphodiesterase 4 Inhibitor

3 molecules in this class, $1.79B combined CY2024 Part D spend across 958K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Phosphodiesterase 4 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $1.79Bcombined across class
Total Rx claims: 958K234K unique beneficiaries
Generic mfrs (active): 14across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Apremilast

Brand: Otezla · 332K Part D claims (CY24) · 61K beneficiaries · First FDA approval: 2020-02-26

5 generic mfrs 1472 plans require PA

Low NADAC$89.95

→

Avg plan cost$93.05

Part D spend $1.68B 1× spread, current vs floor

Class share

94%

of class CY24 spend

View profile →

Roflumilast

Brand: Daliresp · 610K Part D claims (CY24) · 166K beneficiaries · First FDA approval: 2015-07-01

9 generic mfrs 243 plans require PA

Low NADAC$0.320

→

Avg plan cost$3.59

Part D spend $101.4M 11× spread, current vs floor

Class share

of class CY24 spend

View profile →

Crisaborole

Brand: Eucrisa · 16K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2017-01-30

Brand-only (no generics) 227 plans require PA

Low NADAC$10.69

→

Avg plan cost$11.67

Part D spend $13.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.